⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2562270 | 1.00 | — | — | |
| SCHEMBL19551977 | 1.00 | — | — | |
| SCHEMBL9504876 | 0.79 | — | — | |
| SCHEMBL1882577 | 0.79 | — | — | |
| SCHEMBL10525928 | 0.77 | TDP1 (0.50) | — | |
| SCHEMBL11335273 | 0.77 | TSHR (0.34) | — | |
| SCHEMBL6379379 | 0.76 | CTSK (0.39) | — | |
| SCHEMBL9736110 | 0.74 | TSHR (0.36) | — | |
| SCHEMBL10403653 | 0.74 | TSHR (0.36) | — | |
| SCHEMBL11105602 | 0.72 | TSHR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4479137-A1 | IRAK4 INHIBITORS | Astrazeneca AB (SE) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023152349-A1 | IRAK4 INHIBITORS | ASTRAZENECA AB (SE) | 2023-08-17 | — | — | WO | disclosed |
| EP-3700897-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2020-09-02 | — | — | EP | disclosed |
| EP-3452472-A1 | HYDROXYALKYL-SUBSTITUTED HETEROARYLTRIAZOLE DERIVATIVES AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017191114-A1 | HYDROXYALKYL-SUBSTITUTED HETEROARYLTRIAZOLE DERIVATIVES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2017-11-09 | — | — | WO | disclosed |
| EP-3227297-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| WO-2017103670-A1 | 1H-IMIDAZO[4,5-B]PYRIDINYL AND 2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDINYL HETEROCYCLIC BET BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LID. (CA) | 2017-06-22 | — | — | WO | disclosed |
| WO-2016090285-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| EP-2961742-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2906566-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014134566-A2 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014056955-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-17 | — | — | WO | disclosed |
| EP-2558452-A2 | OXAZOLE AND THIAZOLE COMPOUNDS AS KSP INHIBITORS | Novartis AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011128388-A2 | OXAZOLE AND THIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |